New agents for acute myeloid leukemia: is it time for targeted therapies?
- 4 January 2012
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 21 (2), 179-189
- https://doi.org/10.1517/13543784.2012.646082
Abstract
Introduction: The prognosis of acute myeloid leukemia (AML) is improved in the last two decades, even though induction and consolidation chemotherapy has not involved new drugs. The more effective use of well-known agents as well as refinement of supportive care during the inevitable phase of severe pancytopenia following intensive chemotherapy accounts for the reduction of treatment-related death rate. In addition, mortality due to allogeneic and autologous stem cell transplantation has also been reduced, due to adoption of more effective therapies for graft versus host disease and other transplant-related complications. Areas covered: The multitude of chromosomal and molecular abnormalities makes the treatment of AML a challenging prospect. In addition, genetic aberrations are not mutually exclusive and coexist in the leukemic cells. As a consequence, the clinical development of new biologic agents proceeds slowly. Data for this review were identified from PubMed and references from relevant articles published in English from 2000 to 2011. Expert opinion: In Phase II studies, different new agents have been found to be active in AML and are currently under investigation in Phase III trials also in combination with conventional chemotherapy. In the near future, we would have more information about the possibility of introducing new drugs into daily practice.Keywords
This publication has 75 references indexed in Scilit:
- Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markersBlood, 2011
- Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic ImplicationsJournal of Clinical Oncology, 2011
- Therapeutic Advances in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2011
- Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.Current Medicinal Chemistry, 2011
- Genetic Abnormalities and Challenges in the Treatment of Acute Myeloid LeukemiaGenes & Cancer, 2011
- New Prognostic Markers in Acute Myeloid Leukemia: Perspective from the ClinicHematology, 2010
- Acute Myeloid LeukemiaHematology/Oncology Clinics of North America, 2010
- Acute myelogenous leukemiaExperimental Hematology, 2009
- Chemotherapy of acute leukemia in adultsExpert Opinion on Pharmacotherapy, 2009
- Unanswered questions in acute myeloid leukaemiaThe Lancet Oncology, 2004